Add-on Lupuzor Fails Primary Goal but Shows Some Positive Results in Phase 3 Trial for SLE

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a
statistically significant response rate in systemic lupus erythematosus (SLE) patients over
standard care alone, failing the primary goal of a Phase 3 clinical trial, according to top-line
results.

Although not statistically significant, the investigational treatment did, however, show signs
of promise in the trial, including a positive safety profile, with no serious adverse events
reported.

“Lupuzor has demonstrated, in this study, a superior response rate over placebo and its
exceptional safety, giving it, we believe, a compelling product profile,” Tim McCarthy,
ImmuPharma’s chairman, said in a press release.

Upload full article here